<DOC>
	<DOCNO>NCT00276406</DOCNO>
	<brief_summary>Doctors Mayo Clinic study learn pyridostigmine , drug , affect speed food travel stomach , intestine colon , pyridostigmine improve constipation symptom patient diabetes . Pyridostigmine approve Food Drug Administration ( FDA ) routine clinical use , however , use propose study consider investigational .</brief_summary>
	<brief_title>Use Pyridostigmine Constipation Diabetics</brief_title>
	<detailed_description>Chronic constipation diabetes mellitus associate colonic motor dysfunction manage laxative . Cholinesterase inhibitor increase colonic motility . The study evaluate effect cholinesterase inhibitor ( pyridostigmine vs. placebo ) gastrointestinal colonic transit bowel function diabetic patient constipation . After 9-day baseline period , patient diabetes mellitus chronic constipation without defecatory disorder randomize oral placebo pyridostigmine , start 60 mg three time day , increase 60 mg every third day maximum tolerate dose 120 mg three time day ; dose maintain 7 day . Gastrointestinal colonic transit ( assessed scintigraphy ) bowel function evaluate baseline final 3 7 day treatment , respectively .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Pyridostigmine Bromide</mesh_term>
	<criteria>Subjects diabetes mellitus ( Type I type II ) , diagnosed physician . On medical treatment diabetes ( oral medication inject insulin ) least one year Symptomatic constipation least 25 % time past year ( Rome II criterion functional constipation ) 1870 year age Colonoscopy negative obstructive lesion , cancer , inflammatory bowel disease ( IBS ) within last 8 year 50 year age older Able provide write informed consent participate trial Able communicate adequately Investigator comply requirement entire study History pelvic floor dysfunction ( functional GI disorder , eg IBS , nonulcer dyspepsia acceptable ) ; Specifically , patient exclude least 2 follow 3 criterion : History digital evacuation rectum pressure posterior aspect vagina perineum facilitate defecation Examination finding suggestive puborectalis spasm anismus , assessment experience gastroenterologist expertise field ; i.e . high anal sphincter tone rest , failure perineal descent &gt; 1cm straining , tenderness paradoxical contraction puborectalis digital examination Requirement &gt; 200g expel rectal balloon voluntary strain Abdominal surgery appendectomy , cholecystectomy , hysterectomy , tubal ligation , inguinal hernia repair Suspected known gastrointestinal genitourinary obstruction Uncontrolled hypertension ( define &gt; 150/90 rest ) Known cardiac arrhythmia ECG abnormality , i.e . cardiac conduction disturbance ( 2nd 3rd degree atrioventricular ( AV ) block , prolong correct QT interval ( QTc ) ( &gt; 460 msec ) bradycardia ( &lt; 45 beats/minute ) ) Renal insufficiency serum creatinine great 2 mg/dl base read previous 6 month Asthma chronic obstructive pulmonary disease require systemic steroid previous 3 year ( inhaled steroid acceptable ) Current use narcotic , gut prokinetic drug ( eg metoclopramide , domperidone , tegaserod , senekot ) , anticholinergic medication ( eg . Hyoscyamine , belladonna ) , antidiarrheal ( Imodium , Lomotil ) , laxatives fiber supplement , docusate , glycerin suppository . Patients restricted medication must cease use least 48 hour start duration study phase . No rescue laxatives permit within 7 day transit test Patients take investigational medication within past 30 day Known intolerance allergy egg Pregnant breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>